Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Fermé

3.89 2.37

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.74

Max

3.88

Chiffres clés
By Trading Economics
Revenu	-42M -78M
BPA	-0.59
Employés	106
EBITDA	-42M -77M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+134.84% upside

Dividendes
By Acuity
Prochains Résultats	6 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	25M 356M
Ouverture précédente	1.52
Clôture précédente	3.89

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 août 2026, 23:56 UTC

Correlated Moves

Emerson Electric Co's shares are lower in after-market hours, reflecting a decline since Tuesday's close amid broader market sentiment influencing the stock's movement.

25 août 2026, 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, maintaining a position near the upper end of their one-month range amid lower crude oil prices.

25 août 2026, 23:56 UTC

Host Hotels and Resorts, Inc. shares are lower in after-market hours. No specific news was identified to explain the decline, amid falling crude oil prices.

25 août 2026, 23:56 UTC

Correlated Moves

KKR & Co Inc shares are lower in after-market hours, reflecting broader trends in the financial sector amid minimal change since Tuesday's close.

25 août 2026, 23:56 UTC

ETF Constituents

Correlated Moves

Vanguard Morningstar Mid-Cap ETF trades higher after-market, supported by contributions from HWM, PWR, VST, NET, and LHX amid a rising Russell 2000 Index.

25 août 2026, 23:56 UTC

Correlated Moves

M&T Bank Corp shares are lower in after-market trading, influenced by a decline in Wells Fargo and broader market sentiment affecting the banking sector.

25 août 2026, 23:56 UTC

Allogene Therapeutics Inc. is trading roughly flat in after-market hours, maintaining a position near the upper end of its one-month range.

25 août 2026, 23:56 UTC

Correlated Moves

NiSource Inc shares are trading lower in after-market hours, influenced by a decline in Sempra and broader market sentiments affecting utility stocks.

25 août 2026, 23:56 UTC

Toast Inc shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the upper end of their one-month range.

25 août 2026, 23:56 UTC

Baker Hughes Co's shares are higher in after-market trading, with no specific news identified. Broader market trends may be influencing positive sentiment.

25 août 2026, 23:56 UTC

Correlated Moves

Johnson Controls International PLC shares rose in after-market trading, reflecting modest gains amid favorable investor sentiment and a correlation with nVent Electric PLC.

25 août 2026, 23:56 UTC

Correlated Moves

Public Service Enterprise Group Inc. sees modest gains in after-market trading, aligning with broader trends from related companies like DTE Energy Co.

25 août 2026, 23:56 UTC

Correlated Moves

Shares of APA Corp declined in after-market trading, continuing a trend of lower daily finishes, amid falling WTI crude oil prices.

25 août 2026, 23:56 UTC

Fidelity National Information Services shares are trading lower in after-market hours. The asset remains below its 20-day moving average.

25 août 2026, 23:56 UTC

Williams Companies Inc. shares are higher in after-market trading, reflecting a slight gain since Tuesday's close amid declining crude oil prices and lower treasury yields.

25 août 2026, 23:56 UTC

Diamondback Energy shares traded roughly flat in after-market hours, following four consecutive sessions of declines amid lower crude oil prices and treasury yields.

25 août 2026, 23:56 UTC

Correlated Moves

Fifth Third Bancorp remains roughly flat in after-market trading, despite a slight increase in the Dow Jones Index and declining crude oil prices.

25 août 2026, 23:56 UTC

Correlated Moves

Jones Lang LaSalle Inc shares are lower in after-market trading, reflecting a broader decline in the real estate sector alongside Marcus & Millichap Inc.

25 août 2026, 23:52 UTC

Mexico's Business Confidence Remains Low at 48.0 Ahead of Key Survey Amid Mixed Trade Sentiments with the U.S.

25 août 2026, 23:52 UTC

Brazil's Q2 2026 GDP Growth Rate Release Looms Amid Declining Consumer Confidence and Cautious Market Sentiment.

25 août 2026, 23:52 UTC

Brazil's Q2 2026 GDP growth release on September 1 expected to reflect strong government spending amid mixed consumer confidence and rising inflation concerns.

25 août 2026, 23:52 UTC

India's Current Account Balance Release on September 1, 2026 Expected to Impact Market Sentiment Amid Rising Import Costs and Geopolitical Pressures.

25 août 2026, 23:52 UTC

Brazil's Central Bank to Announce SELIC Rate Decision Amid Global Monetary Policy Uncertainty on August 31, 2026.

25 août 2026, 23:52 UTC

Social Media

Warner Bros Discovery Inc shares traded lower in after-market hours amid ongoing scrutiny in the antitrust case involving Paramount and related legal developments.

25 août 2026, 23:52 UTC

UniFirst Corp shares declined in after-market trading, despite a favorable macro environment with falling crude oil prices and lower Treasury yields.

25 août 2026, 23:51 UTC

DraftKings shares are higher in after-market trading amid favorable market conditions and a decline in crude oil prices. No specific news was identified.

25 août 2026, 23:51 UTC

Travel + Leisure Co shares are higher in after-market hours. No specific company news was identified, but declining crude oil prices may be influencing sentiment.

25 août 2026, 23:51 UTC

Correlated Moves

American Water Works shares are higher in after-market trading, supported by a decline in crude oil prices and easing inflation concerns.

25 août 2026, 23:51 UTC

Asia equity markets mixed as investors react to geopolitical tensions, falling crude oil prices, and await key U.S. economic data releases.

25 août 2026, 23:51 UTC

Mixed trading in Europe as Germany's Ifo index rises, while France's consumer confidence dips; U.S. markets gain on falling oil prices and tech stock rallies ahead of key earnings.

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

134.84% hausse

Prévisions sur 12 Mois

Moyen 8.83 USD 134.84%

Haut 11 USD

Bas 5 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.